Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seladelpar in NASH
NCT03551522Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Apr 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of seladelpar in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Gilead Sciences. Primary endpoint: Percentage Change From Baseline in Magnetic Resonance Imaging-proton Density Fat Fraction at 12 weeks. Started Apr 2018; status: terminated.
02
Drugs
seladelpar
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03551522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03551522.